ImmunityBio is a clinical-stage biotechnology company focused on immunotherapies for cancer and infectious disease. Its core commercial product is ANKTIVA (nogapendekin alfa inbakicept), the first FDA-approved IL-15 receptor superagonist, which works by stimulating NK cells and CD8+ T cells to attack tumors while avoiding the immunosuppressive effects that limit many existing therapies. ANKTIVA's first approved indication is BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, where it is administered directly into the bladder alongside BCG. ImmunityBio sells ANKTIVA in the U.S. through specialty distributors and a direct sales force targeting urologists and oncologists, and has partnered with Accord Healthcare and regional distributors for EU and Middle East distribution. Revenue is driven by volume growth in the approved bladder cancer indication, with label expansion and geographic expansion as the key growth levers. Beyond bladder cancer, ImmunityBio is advancing ANKTIVA in lung cancer (NSCLC), glioblastoma, pancreatic cancer, and a tumor-agnostic lymphopenia rescue program, among others. The company also has two complementary platforms — adenovirus-based cancer vaccines and off-the-shelf allogeneic CAR-NK cell therapies — which it combines with ANKTIVA in multi-modal treatment regimens. ImmunityBio is pre-profitability and funds operations through capital raises and debt, with costs driven by clinical trials, manufacturing, and commercial infrastructure.